Theratechnologies’ IV Push Form Of HIV Treatment At Par With IV Infusion
Theratechnologies Inc (NASDAQ:THTX) has announced results from a study evaluating an intravenous (IV) push form of Trogarzo (ibalizumab-uiyk) for HIV-1 infection.…
Theratechnologies Announces Results For Trogarzo IV Push Administration; Says TMB-302 Study Results Demonstrate There Was No Difference In Pharmacokinetics Between IV Push And IV Infusion
Theratechnologies Inc. (Theratechnologies, or Company) (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that a study
10 Biggest Price Target Changes For Thursday
Canaccord Genuity cut Theratechnologies Inc. (NASDAQ: THTX) price target from $8 to $3. Theratechnologies shares gained 4.5% to close at $3.71 on Wednesday.
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)
Theratechnologies In Search Of Potential Partner For Late-Stage NASH Study Of Tesamorelin, Reports Q2 Earnings
Theratechnologies Inc (NASDAQ:THTX) has completed discussions with the FDA and European Medicines Agency regarding its proposed trial design and protocol for…
Theratechnologies Q2 EPS $(0.07) Up From $(0.08) YoY
Theratechnologies (NASDAQ:THTX) reported quarterly losses of $(0.07) per share. This is a 12.5 percent increase over losses of $(0.08) per share from the same period last year.
Earnings Scheduled For July 15, 2021
Companies Reporting Before The Bell
• Truist Financial (NYSE:TFC) is estimated to report quarterly earnings at $1.17 per share on revenue of $5.47 billion.
Theratechnologies Peptide-Drug Conjugate Shows Better Anti-Metastatic Activity Compared With Docetaxel Alone
Theratechnologies Inc (NASDAQ:THTX) has announced new preclinical in vivo findings on its peptide-drug conjugate (PDC), TH1902. The results demonstrate that TH1902…
Theratechnologies Announces New Preclinical Findings for Its Lead Investigational Peptide-Drug Conjugate TH1902 for the Potential Treatment of Metastatic Cancers
Demonstrates better anti-metastatic activity compared with docetaxel alone
Company to host webcast on its oncology program today at 11:00 a.m. ET
MONTREAL, June 21, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc.